Hepatocyte growth factor (HGF) binding proteins

US7935502B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• May Han · Brookline, US
• S. Kirk Wright · Waltham, US
• William M. Winston, Jr. · Marlborough, US
• Lyne Breault · Brookline, US
• Jie Lin · Dedham, US
• Bijan Etemad-Gilbertson · Brookline, US
• Christine Knuehl · Natick, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Dec 7, 2009
• Grant date: May 3, 2011
• Expiry date: Dec 7, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.